Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib in Metastatic Urothelial Cancer
NCT00471536Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2008
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in urothelial carcinoma (UC), sponsored by National Cancer Institute. Primary endpoint: Best Tumor Response (Complete [CR] or Partial Response [PR]). Started Aug 2008; status: completed.
02
Drugs
pazopanib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT00471536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00471536.